How AI in healthcare is shifting toward real-world clinical adoption in India

AI-driven healthcare startups in India are being evaluated on real-world clinical impact and system integration rather than technological novelty, as investors shift focus toward scalable, adoption-ready solutions.

Industry experts say the emphasis has moved from proof-of-concept AI tools to applications that can demonstrably reduce clinical burden, improve patient access, and integrate into existing hospital workflows. Within this shift, diagnostic applications are emerging as the most commercially viable segment, given their faster adoption cycles and clearer value proposition in addressing India’s shortage of medical specialists.

Experts note that while oncology-focused AI solutions hold long-term potential due to their role in complex disease management, they typically require deeper clinical validation and longer regulatory and deployment timelines. Tuberculosis (TB)-related AI solutions, on the other hand, are attracting interest for their ability to scale within public health systems, though their effectiveness is increasingly seen as higher when embedded within broader diagnostic platforms rather than as standalone tools.
According to Gaurav Singh, CEO of Blockchain For Impact (BFI), investor priorities have evolved significantly, with greater scrutiny on whether AI solutions can function effectively in real hospital environments rather than controlled settings. “The key questions are whether it reduces the burden on doctors, reaches patients faster, and works in real clinical workflows,” he said.

The sector is also witnessing growing interest in catalytic funding models aimed at bridging the gap between early-stage innovation and commercial deployment. Such models are being used to support startups beyond initial funding through clinical validation, real-world pilots, and market access support.

BFI, for instance, has committed $50 million toward its Innovation Full Stack initiative, which focuses on advancing healthcare innovations from prototype stage to adoption-ready solutions. The organization says this approach helps reduce execution risk for investors by ensuring technologies are tested in practical healthcare settings before scaling.

Industry experts say such blended capital and validation models are becoming increasingly important in deep-tech healthcare investing, where long development cycles, regulatory requirements, and fragmented healthcare infrastructure often slow down commercialization.